Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group PLC, alleging that the company made misleading statements regarding the health risks associated with its Enfamil infant formula, particularly for preterm infants [3][4]. Group 1: Class Action Details - The class action represents investors who purchased Reckitt Benckiser securities between January 13, 2021, and July 28, 2024, with a deadline for filing a lead plaintiff motion set for August 4, 2025 [1]. - The lawsuit claims that Reckitt Benckiser failed to disclose the increased risk of Necrotizing Enterocolitis (NEC) for preterm infants consuming its cow's milk-based formula [3]. Group 2: Legal Allegations and Impact - A jury found Mead Johnson, a subsidiary of Reckitt Benckiser, negligent in a case related to NEC, resulting in a $60 million verdict on March 15, 2024, which led to a nearly 14% drop in Reckitt Benckiser's American Depositary Shares (ADSs) [4]. - Following a related case that awarded $495 million in damages for NEC caused by a competing formula, Reckitt Benckiser's ADSs fell nearly 9% on July 29, 2024 [5]. Group 3: Company Background - Reckitt Benckiser is a U.K.-based global consumer goods company that acquired Mead Johnson Nutrition for $19.7 billion in 2017 [2].

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that negatively impacted investors between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Reckitt Benckiser Group plc made false statements regarding the safety of its cow's milk-based formula, Enfamil, which allegedly increased the risk of NEC in preterm infants [2]. - It is alleged that the company concealed the impact of these risks on its sales and exposure to legal claims, leading to materially false and misleading positive statements about its business and operations [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that negatively impacted investors between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Reckitt Benckiser's cow's milk-based formula, Enfamil, increased the risk of preterm infants developing NEC, which was not disclosed [2]. - It is alleged that the company misrepresented the impact of these risks on its sales and exposure to legal claims, leading to materially false and misleading statements about its business and prospects [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Reckitt Benckiser Group plc (OTC PINK: RBGLY). Shareholders who purchased shares of RBGLY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: January 13, 2021 to July 28, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issue ...

Core Points - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud affecting investors between January 13, 2021, and July 28, 2024 [1][2] - The lawsuit claims that Reckitt's cow's milk-based formula, Enfamil, posed an increased risk of NEC in preterm infants, which was not disclosed, impacting sales and exposing the company to legal claims [2] - Investors have until August 4, 2025, to request to be appointed as lead plaintiff, with no costs required for participation in the lawsuit [3] Company Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

Core Viewpoint - Reckitt Benckiser Group has agreed to sell its Essential Home business to Advent International for $4.8 billion while retaining a 30% stake in the business [1] Group 1 - The transaction value for the sale of Essential Home is $4.8 billion [1] - Reckitt Benckiser will maintain a 30% ownership interest in the Essential Home business post-sale [1]

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that negatively impacted investors between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Reckitt Benckiser's cow's milk-based formula, Enfamil, posed an increased risk of NEC (Necrotizing Enterocolitis) in preterm infants, which was not disclosed [2]. - It is alleged that the company misrepresented the impact of these risks on its sales and legal exposure, leading to materially false and misleading statements about its business and prospects [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].

Core Viewpoint - Class actions have been initiated against Vestis Corporation, Reckitt Benckiser Group, and Tempus AI, highlighting significant legal challenges and potential financial implications for these companies [1][4][6]. Group 1: Vestis Corporation (NYSE: VSTS) - The class period for Vestis is from May 2, 2024, to May 6, 2025, with a lead plaintiff deadline of August 8, 2025 [2]. - The complaint alleges that Vestis made misleading statements about its business growth capabilities, particularly regarding customer retention and revenue generation [2]. - Following a disappointing financial report on May 7, 2025, Vestis' stock price plummeted from $8.71 to $5.44, a decline of approximately 37.54% in one day [3]. Group 2: Reckitt Benckiser Group plc (OTC: RBGLY) - The class period for Reckitt is from January 13, 2021, to July 28, 2024, with a lead plaintiff deadline of August 4, 2025 [4]. - Over 500 lawsuits have been filed against Reckitt, alleging failure to warn about the risks associated with its cow's milk-based formula, Enfamil, which is linked to a serious intestinal disease in premature infants [4][5]. - The allegations include misleading statements regarding the safety of Reckitt's products and the potential impact on sales and legal exposure [5]. Group 3: Tempus AI, Inc. (NASDAQ: TEM) - The class period for Tempus is from August 6, 2024, to May 27, 2025, with a lead plaintiff deadline of August 11, 2025 [6]. - The complaint claims that Tempus failed to disclose significant issues, including inflated contract values and questionable business practices that could jeopardize its financial stability [6]. - Following a critical report from Spruce Point Capital Management on May 28, 2025, Tempus' stock price fell from $65.87 to $53.20, a decrease of 19.23% [7][8].

Core Viewpoint - The Rosen Law Firm is reminding purchasers of Reckitt Benckiser Group PLC's American Depositary Shares (ADSs) of a class action lawsuit with a lead plaintiff deadline of August 4, 2025, for those who bought shares between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Class Action Details - Investors who purchased Reckitt ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the August 4, 2025 deadline [2][4]. - The lawsuit alleges that Reckitt failed to warn investors about the increased risk of necrotizing enterocolitis (NEC) in preterm infants due to its cow's milk-based formula, Enfamil, which misled investors regarding the company's business prospects [4]. Group 2: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [3]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [3].

Core Viewpoint - The Rosen Law Firm is reminding purchasers of Reckitt Benckiser Group PLC's American Depositary Shares (ADSs) of a class action lawsuit with a lead plaintiff deadline of August 4, 2025, for those who bought shares between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Class Action Details - Investors who purchased Reckitt ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The lawsuit alleges that Reckitt failed to warn investors about the increased risk of necrotizing enterocolitis (NEC) in preterm infants due to its cow's milk-based formula, Enfamil, which misled investors regarding the company's business prospects [4]. Group 2: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3].